A phase II trial of the intranasal respiratory syncytial virus (RSV) vaccine, SynGEM, in patients with RSV infection

Trial Profile

A phase II trial of the intranasal respiratory syncytial virus (RSV) vaccine, SynGEM, in patients with RSV infection

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Respiratory syncytial virus vaccine-Mucosis (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2016 According to Mucosis B.V media release, this trial is due to start in mid-2017.
    • 22 Jan 2016 New trial record
    • 20 Jan 2016 The company plans to advance the Investigational Medicinal Product Dossier (IMPD) submission materials for clinical trial approval in 2016, according to a Mucosis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top